This time, her baby did test positive for SMA type 1, a severe neurodegenerative genetic condition that typically results in ...

A new weight-based secukinumab formulation provides a new option for treatment of adolescents with moderate-to-severe hidradenitis suppurativa (HS) with the FDA’s approval, according to a press ...

The FDA granted the approval following findings from the pivotal POETYK PsA-I and POETYK PsA-II Phase III studies.

First published in 2010, the EULAR recommendations for the management of RA, the most frequent inflammatory rheumatic disease ...

The FDA has approved deucravacitinib for adults with active psoriatic arthritis, according to a press release from Bristol ...

The FDA accepted a New Drug Application with Priority Review for brepocitinib, an oral TYK2/JAK1 inhibitor, for the treatment of dermatomyositis.

March 11 (Reuters) - Regenxbio said on Wednesday that interim data from a early-to-mid stage study of its experimental gene therapy in patients with Duchenne muscular dystrophy showed continued ...

In clinical trials, more than half of all patients treated with deucravacitinib achieved at least 20% improvement in American College of Rheumatology response criteria.

Gepotidacin and nitrofurantoin demonstrate similar efficacy in reducing symptom severity and restoring daily function in women with uncomplicated UTI.

The FDA approved secukimumab for children aged 12 years and older with moderate to severe hidradenitis suppurativa, Novartis announced in a press release.The approval makes secukinumab (Cosentyx) the ...

Mayor Zohran Mamdani appointed Stanley Richards as the new commissioner of the city’s Department of Correction on Saturday. Richards will become the first formerly incarcerated person to lead the city ...

Oral TYK2 inhibitor deucravacitinib receives FDA approval for active psoriatic arthritis based on significantly improved ACR20 response rates.